Welcome to LookChem.com Sign In|Join Free

CAS

  • or

7101-51-1

Post Buying Request

7101-51-1 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier
  • Methyl (2s)-2-amino-3-(3,4-dihydroxyphenyl)propanoate

    Cas No: 7101-51-1

  • USD $ 1.5-1.5 / Metric Ton

  • 1 Metric Ton

  • 1000 Metric Ton/Day

  • KAISA GROUP INC
  • Contact Supplier

7101-51-1 Usage

Description

CHF-1301 was launched as an injection in Italy for the treatment of patients with Parkinson's disease, particularly those with complications in their clinical responses. CHF-1301 is the methyl ester of L-Dopa (levodopa), the immediate precursor of dopamine. Thus, this prodrug is more soluble in water at physiological pH, better absorbed and slowly transformed into levodopa in vivo; it consequently improves the duration of action and prevents the rapid fluctuations in response or involontary movements (dyskinesia) observed during chronic treatment with levodopa. In patients with a delayed effect of levodopa (on-phenomenon) or a severe resistance to L-Dopa (off-phenomenon), CHF- 1301 significantly improves the onset and the stability of the'response.

Originator

Chiesi Farmaceutici SpA (Italy)

Brand name

Levomet

Check Digit Verification of cas no

The CAS Registry Mumber 7101-51-1 includes 7 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 4 digits, 7,1,0 and 1 respectively; the second part has 2 digits, 5 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 7101-51:
(6*7)+(5*1)+(4*0)+(3*1)+(2*5)+(1*1)=61
61 % 10 = 1
So 7101-51-1 is a valid CAS Registry Number.
InChI:InChI=1/C10H13NO4/c1-15-10(14)7(11)4-6-2-3-8(12)9(13)5-6/h2-3,5,7,12-13H,4,11H2,1H3/t7-/m0/s1

7101-51-1SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 18, 2017

Revision Date: Aug 18, 2017

1.Identification

1.1 GHS Product identifier

Product name methyl (2S)-2-amino-3-(3,4-dihydroxyphenyl)propanoate

1.2 Other means of identification

Product number -
Other names 3-Hydroxy-L-tyrosine methyl ester

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:7101-51-1 SDS

7101-51-1Synthetic route

methanol
67-56-1

methanol

levodopa
59-92-7

levodopa

L-DOPA methyl ester
7101-51-1

L-DOPA methyl ester

Conditions
ConditionsYield
With thionyl chloride at 0 - 20℃; Inert atmosphere;100%
With thionyl chloride Reflux;90%
With hydrogenchloride
L-Tyr-OMe
1080-06-4

L-Tyr-OMe

L-DOPA methyl ester
7101-51-1

L-DOPA methyl ester

Conditions
ConditionsYield
With 1,3,6,8-tetra-n-butylpyrimido<5,4-g>pteridine-2,4,5,7(1H,3H,6H,8H)-tetrone 10-oxide In acetonitrile for 0.666667h; Irradiation;25%
(+/-)-3-(3,4-dihydroxyphenyl)-2-methyl-DL-alanine
7101-51-1, 41439-83-2, 71855-43-1

(+/-)-3-(3,4-dihydroxyphenyl)-2-methyl-DL-alanine

A

levodopa
59-92-7

levodopa

B

L-DOPA methyl ester
7101-51-1

L-DOPA methyl ester

C

(R)-(3,4-dihydroxyphenyl)alanine methyl ester
71855-43-1

(R)-(3,4-dihydroxyphenyl)alanine methyl ester

Conditions
ConditionsYield
With Alcalase; water In tert-butyl alcohol at 25℃; for 2.5h; pH=8.5; kinetic resolution; Title compound not separated from byproducts;
N-[(phenylmethoxy)carbonyl]-3-hydroxy-O-(phenylmethyl)-L-tyrosine methyl ester
105229-41-2

N-[(phenylmethoxy)carbonyl]-3-hydroxy-O-(phenylmethyl)-L-tyrosine methyl ester

L-DOPA methyl ester
7101-51-1

L-DOPA methyl ester

Conditions
ConditionsYield
With hydrogen; palladium on activated charcoal In dichloromethane
(S)-3-(3-Acetoxy-4-benzyloxy-phenyl)-2-benzyloxycarbonylamino-propionic acid methyl ester

(S)-3-(3-Acetoxy-4-benzyloxy-phenyl)-2-benzyloxycarbonylamino-propionic acid methyl ester

L-DOPA methyl ester
7101-51-1

L-DOPA methyl ester

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: 453 mg / NH3 / CH2Cl2; methanol / 1 h
2: H2 / Pd/C / CH2Cl2
View Scheme
L-tyrosine
60-18-4

L-tyrosine

L-DOPA methyl ester
7101-51-1

L-DOPA methyl ester

Conditions
ConditionsYield
Multi-step reaction with 7 steps
1: 67 percent / AlCl3 / nitrobenzene / 6 h / 100 °C
2: 74 percent / SOCl2 / Heating
3: 93 percent / aq. Na2CO3 / diethyl ether / 3 h / 25 °C
4: 60 percent / K2CO3; (n-Bu)4NI / dimethylformamide / 6 h / 20 °C
5: mCPBA / CH2Cl2 / 40 °C
6: 453 mg / NH3 / CH2Cl2; methanol / 1 h
7: H2 / Pd/C / CH2Cl2
View Scheme
L-3-(3-acetyl-4-hydroxyphenyl)-N-(benzyloxycarbonyl)alanine methyl ester
110774-03-3

L-3-(3-acetyl-4-hydroxyphenyl)-N-(benzyloxycarbonyl)alanine methyl ester

L-DOPA methyl ester
7101-51-1

L-DOPA methyl ester

Conditions
ConditionsYield
Multi-step reaction with 4 steps
1: 60 percent / K2CO3; (n-Bu)4NI / dimethylformamide / 6 h / 20 °C
2: mCPBA / CH2Cl2 / 40 °C
3: 453 mg / NH3 / CH2Cl2; methanol / 1 h
4: H2 / Pd/C / CH2Cl2
View Scheme
(S)-3-(3-acetyl-4-hydroxyphenyl)-2-aminopropanoic acid hydrochloride
32404-28-7

(S)-3-(3-acetyl-4-hydroxyphenyl)-2-aminopropanoic acid hydrochloride

L-DOPA methyl ester
7101-51-1

L-DOPA methyl ester

Conditions
ConditionsYield
Multi-step reaction with 6 steps
1: 74 percent / SOCl2 / Heating
2: 93 percent / aq. Na2CO3 / diethyl ether / 3 h / 25 °C
3: 60 percent / K2CO3; (n-Bu)4NI / dimethylformamide / 6 h / 20 °C
4: mCPBA / CH2Cl2 / 40 °C
5: 453 mg / NH3 / CH2Cl2; methanol / 1 h
6: H2 / Pd/C / CH2Cl2
View Scheme
methyl (S)-3-(3-acetyl-4-hydroxyphenyl)-2-aminopropanoate monohydrochloride
57085-32-2

methyl (S)-3-(3-acetyl-4-hydroxyphenyl)-2-aminopropanoate monohydrochloride

L-DOPA methyl ester
7101-51-1

L-DOPA methyl ester

Conditions
ConditionsYield
Multi-step reaction with 5 steps
1: 93 percent / aq. Na2CO3 / diethyl ether / 3 h / 25 °C
2: 60 percent / K2CO3; (n-Bu)4NI / dimethylformamide / 6 h / 20 °C
3: mCPBA / CH2Cl2 / 40 °C
4: 453 mg / NH3 / CH2Cl2; methanol / 1 h
5: H2 / Pd/C / CH2Cl2
View Scheme
L-3-(3-acetyl-4-(benzyloxy)phenyl)-N-(benzyloxycarbonyl)alanine methyl ester
105205-69-4

L-3-(3-acetyl-4-(benzyloxy)phenyl)-N-(benzyloxycarbonyl)alanine methyl ester

L-DOPA methyl ester
7101-51-1

L-DOPA methyl ester

Conditions
ConditionsYield
Multi-step reaction with 3 steps
1: mCPBA / CH2Cl2 / 40 °C
2: 453 mg / NH3 / CH2Cl2; methanol / 1 h
3: H2 / Pd/C / CH2Cl2
View Scheme
levodopa
59-92-7

levodopa

L-DOPA methyl ester
7101-51-1

L-DOPA methyl ester

Conditions
ConditionsYield
With thionyl chloride In methanol for 18h;
methyl (S)-2-(tert-butoxycarbonylamino)-3-(3,4-dihydroxyphenyl)propanoate
37169-36-1

methyl (S)-2-(tert-butoxycarbonylamino)-3-(3,4-dihydroxyphenyl)propanoate

L-DOPA methyl ester
7101-51-1

L-DOPA methyl ester

Conditions
ConditionsYield
With hydrogenchloride In ethyl acetate
L-DOPA methyl ester
7101-51-1

L-DOPA methyl ester

Diethyl ketomalonate
609-09-6

Diethyl ketomalonate

6,7-dihydroxy-3,4-dihydro-2H-isoquinoline-1,1,3-tricarboxylic acid diethyl ester methyl ester

6,7-dihydroxy-3,4-dihydro-2H-isoquinoline-1,1,3-tricarboxylic acid diethyl ester methyl ester

Conditions
ConditionsYield
With trifluoroacetic acid In toluene at 85℃; for 2h; Pictet-Spegler condensation;98%
L-DOPA methyl ester
7101-51-1

L-DOPA methyl ester

3,4,5-trimethoxy-benzaldehyde
86-81-7

3,4,5-trimethoxy-benzaldehyde

(1S,3S)-6,7-Dihydroxy-1-(3,4,5-trimethoxy-phenyl)-1,2,3,4-tetrahydro-isoquinoline-3-carboxylic acid methyl ester
128049-96-7

(1S,3S)-6,7-Dihydroxy-1-(3,4,5-trimethoxy-phenyl)-1,2,3,4-tetrahydro-isoquinoline-3-carboxylic acid methyl ester

Conditions
ConditionsYield
With sodium acetate In acetic acid for 18h; Ambient temperature;95%
di-tert-butyl dicarbonate
24424-99-5

di-tert-butyl dicarbonate

L-DOPA methyl ester
7101-51-1

L-DOPA methyl ester

methyl (S)-2-(tert-butoxycarbonylamino)-3-(3,4-dihydroxyphenyl)propanoate
37169-36-1

methyl (S)-2-(tert-butoxycarbonylamino)-3-(3,4-dihydroxyphenyl)propanoate

Conditions
ConditionsYield
With triethylamine In methanol at 20℃;95%
With sodium hydrogencarbonate In tetrahydrofuran at 0 - 20℃; for 2h; Product distribution / selectivity;90%
With N-ethyl-N,N-diisopropylamine In tetrahydrofuran at 20℃; for 1h;13.4 g
di-tert-butyl dicarbonate
24424-99-5

di-tert-butyl dicarbonate

L-DOPA methyl ester
7101-51-1

L-DOPA methyl ester

(S)-(+)-2-tert-butoxycarbonylamino-3-(3,4-dimethoxyphenyl)propionic acid methyl ester
138908-56-2

(S)-(+)-2-tert-butoxycarbonylamino-3-(3,4-dimethoxyphenyl)propionic acid methyl ester

Conditions
ConditionsYield
Stage #1: L-DOPA methyl ester With thionyl chloride In methanol at 50℃; for 3h; Inert atmosphere; Cooling with ice;
Stage #2: di-tert-butyl dicarbonate With sodium hydrogencarbonate In tetrahydrofuran at 20℃; for 1h; Cooling with ice;
Stage #3: With potassium carbonate; dimethyl sulfate In acetone at 20℃; Reflux;
94.4%
L-DOPA methyl ester
7101-51-1

L-DOPA methyl ester

(3aR,6R,6aR)-2,2-dimethyl-6-(tosyloxymethyl)-tetrahydro-2H-furo[3,4-d]-1,3-dioxol-4-ol
950182-24-8

(3aR,6R,6aR)-2,2-dimethyl-6-(tosyloxymethyl)-tetrahydro-2H-furo[3,4-d]-1,3-dioxol-4-ol

C18H23NO7
1541171-38-3

C18H23NO7

Conditions
ConditionsYield
In dichloromethane at 20℃; for 10h; Pictet-Spengler Synthesis; Inert atmosphere; diastereoselective reaction;88%
L-DOPA methyl ester
7101-51-1

L-DOPA methyl ester

chloroformic acid ethyl ester
541-41-3

chloroformic acid ethyl ester

(S)-3-(3,4-Dihydroxy-phenyl)-2-ethoxycarbonylamino-propionic acid methyl ester
682801-34-9

(S)-3-(3,4-Dihydroxy-phenyl)-2-ethoxycarbonylamino-propionic acid methyl ester

Conditions
ConditionsYield
With iPrEtN In dichloromethane78%
L-DOPA methyl ester
7101-51-1

L-DOPA methyl ester

D-lyxose tosylate

D-lyxose tosylate

C18H23NO7
1541171-41-8

C18H23NO7

Conditions
ConditionsYield
In dichloromethane at 20℃; for 47h; Pictet-Spengler Synthesis; Inert atmosphere; diastereoselective reaction;78%
C23H17N3O4
137130-06-4

C23H17N3O4

L-DOPA methyl ester
7101-51-1

L-DOPA methyl ester

methyl (2S)-3-(3,4-dihydroxyphenyl)-2-[(2-{3-[4-(1H-3-indolyl)-1-methyl-2,5-dioxo-2,5-dihydro-1H-3-pyrrolyl]-1H-1-indolyl}acetyl)amino]propanoate
1246473-68-6

methyl (2S)-3-(3,4-dihydroxyphenyl)-2-[(2-{3-[4-(1H-3-indolyl)-1-methyl-2,5-dioxo-2,5-dihydro-1H-3-pyrrolyl]-1H-1-indolyl}acetyl)amino]propanoate

Conditions
ConditionsYield
With dmap; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride In dichloromethane at 20℃;73%
1-pyrenemethanol
24463-15-8

1-pyrenemethanol

L-DOPA methyl ester
7101-51-1

L-DOPA methyl ester

1,1'-carbonyldiimidazole
530-62-1

1,1'-carbonyldiimidazole

N-[(pyren-1-yl)methoxycarbonyl]-L-3,4-dihydroxyphenylalanine methyl ester
1251958-98-1

N-[(pyren-1-yl)methoxycarbonyl]-L-3,4-dihydroxyphenylalanine methyl ester

Conditions
ConditionsYield
Stage #1: 1-pyrenemethanol; 1,1'-carbonyldiimidazole In N,N-dimethyl-formamide at 0 - 20℃; for 1h;
Stage #2: L-DOPA methyl ester In N,N-dimethyl-formamide for 12h;
40%
L-DOPA methyl ester
7101-51-1

L-DOPA methyl ester

4'-O-demethyl-4β-(4''-carboxyanilino)-4-desoxypodophyllotoxin
152833-18-6

4'-O-demethyl-4β-(4''-carboxyanilino)-4-desoxypodophyllotoxin

(S)-3-(3,4-Dihydroxy-phenyl)-2-{4-[(5S,5aS,8aR,9R)-9-(4-hydroxy-3,5-dimethoxy-phenyl)-8-oxo-5,5a,6,8,8a,9-hexahydro-furo[3',4':6,7]naphtho[2,3-d][1,3]dioxol-5-ylamino]-benzoylamino}-propionic acid methyl ester

(S)-3-(3,4-Dihydroxy-phenyl)-2-{4-[(5S,5aS,8aR,9R)-9-(4-hydroxy-3,5-dimethoxy-phenyl)-8-oxo-5,5a,6,8,8a,9-hexahydro-furo[3',4':6,7]naphtho[2,3-d][1,3]dioxol-5-ylamino]-benzoylamino}-propionic acid methyl ester

Conditions
ConditionsYield
With dmap; dicyclohexyl-carbodiimide In tetrahydrofuran at 20℃;33%
Fmoc-Gly-H

Fmoc-Gly-H

L-DOPA methyl ester
7101-51-1

L-DOPA methyl ester

A

(1R,3S)-1-[(N-fluorenyl)methoxycarbonyl]aminomethyl-3-methoxycarbonyl-1,2,3,4-tetrahydro-6,7-dihydroxyisoquinoline

(1R,3S)-1-[(N-fluorenyl)methoxycarbonyl]aminomethyl-3-methoxycarbonyl-1,2,3,4-tetrahydro-6,7-dihydroxyisoquinoline

B

(1S,3S)-1-[(N-fluorenyl)methoxycarbonyl]aminomethyl-3-methoxycarbonyl-1,2,3,4-tetrahydro-6,7-dihydroxyisoquinoline

(1S,3S)-1-[(N-fluorenyl)methoxycarbonyl]aminomethyl-3-methoxycarbonyl-1,2,3,4-tetrahydro-6,7-dihydroxyisoquinoline

C

(1R,3S)-1-[(9H-Fluoren-1-ylmethoxycarbonylamino)-methyl]-7,8-dihydroxy-1,2,3,4-tetrahydro-isoquinoline-3-carboxylic acid methyl ester

(1R,3S)-1-[(9H-Fluoren-1-ylmethoxycarbonylamino)-methyl]-7,8-dihydroxy-1,2,3,4-tetrahydro-isoquinoline-3-carboxylic acid methyl ester

D

(1S,3S)-1-[(9H-Fluoren-1-ylmethoxycarbonylamino)-methyl]-7,8-dihydroxy-1,2,3,4-tetrahydro-isoquinoline-3-carboxylic acid methyl ester

(1S,3S)-1-[(9H-Fluoren-1-ylmethoxycarbonylamino)-methyl]-7,8-dihydroxy-1,2,3,4-tetrahydro-isoquinoline-3-carboxylic acid methyl ester

Conditions
ConditionsYield
With trifluoroacetic acid In dichloromethane at 20℃; for 6h; Pictet-Spengler condensation;A 29%
B 19%
C n/a
D n/a
Fmoc-Ala-H

Fmoc-Ala-H

L-DOPA methyl ester
7101-51-1

L-DOPA methyl ester

A

(1R,3S,1'S)-1-{[1'-(N-fluorenyl)methoxycarbonyl]amino}ethyl-3-methoxycarbonyl-1,2,3,4-tetrahydro-6,7-dihydroxyisoquinoline

(1R,3S,1'S)-1-{[1'-(N-fluorenyl)methoxycarbonyl]amino}ethyl-3-methoxycarbonyl-1,2,3,4-tetrahydro-6,7-dihydroxyisoquinoline

B

(1S,3S,1'S)-1-{[1'-(N-fluorenyl)methoxycarbonyl]amino}ethyl-3-methoxycarbonyl-1,2,3,4-tetrahydro-6,7-dihydroxyisoquinoline

(1S,3S,1'S)-1-{[1'-(N-fluorenyl)methoxycarbonyl]amino}ethyl-3-methoxycarbonyl-1,2,3,4-tetrahydro-6,7-dihydroxyisoquinoline

C

(1S,3S)-1-[(S)-1-(9H-Fluoren-1-ylmethoxycarbonylamino)-ethyl]-7,8-dihydroxy-1,2,3,4-tetrahydro-isoquinoline-3-carboxylic acid methyl ester

(1S,3S)-1-[(S)-1-(9H-Fluoren-1-ylmethoxycarbonylamino)-ethyl]-7,8-dihydroxy-1,2,3,4-tetrahydro-isoquinoline-3-carboxylic acid methyl ester

D

(1R,3S)-1-[(S)-1-(9H-Fluoren-1-ylmethoxycarbonylamino)-ethyl]-7,8-dihydroxy-1,2,3,4-tetrahydro-isoquinoline-3-carboxylic acid methyl ester

(1R,3S)-1-[(S)-1-(9H-Fluoren-1-ylmethoxycarbonylamino)-ethyl]-7,8-dihydroxy-1,2,3,4-tetrahydro-isoquinoline-3-carboxylic acid methyl ester

Conditions
ConditionsYield
With trifluoroacetic acid In dichloromethane at 20℃; for 6h; Pictet-Spengler condensation;A 28%
B 23%
C n/a
D n/a
Fmoc-Phe-H

Fmoc-Phe-H

L-DOPA methyl ester
7101-51-1

L-DOPA methyl ester

A

(1S,3S,1'S)-1-{[1'-(N-fluorenyl)methoxycarbonyl]amino}phenylethyl-3-methoxycarbonyl-1,2,3,4-tetrahydro-6,7-dihydroxyisoquinoline

(1S,3S,1'S)-1-{[1'-(N-fluorenyl)methoxycarbonyl]amino}phenylethyl-3-methoxycarbonyl-1,2,3,4-tetrahydro-6,7-dihydroxyisoquinoline

B

(1R,3S,1'S)-1-{[1'-(N-fluorenyl)methoxycarbonyl]amino}phenylethyl-3-methoxycarbonyl-1,2,3,4-tetrahydro-6,7-dihydroxyisoquinoline

(1R,3S,1'S)-1-{[1'-(N-fluorenyl)methoxycarbonyl]amino}phenylethyl-3-methoxycarbonyl-1,2,3,4-tetrahydro-6,7-dihydroxyisoquinoline

Conditions
ConditionsYield
With trifluoroacetic acid In dichloromethane at 20℃; for 6h; Pictet-Spengler condensation;A 25%
B 26%
3-(benzyloxycarbonylamino)propanoic acid
2304-94-1

3-(benzyloxycarbonylamino)propanoic acid

L-DOPA methyl ester
7101-51-1

L-DOPA methyl ester

β-alanyl-L-dopa
21612-39-5

β-alanyl-L-dopa

Conditions
ConditionsYield
(i) Et3N, POCl3, (ii) aq. NaOH, (iii) H2, Pd-C; Multistep reaction;
3-(4-iodophenyl)propionic acid
1643-29-4

3-(4-iodophenyl)propionic acid

L-DOPA methyl ester
7101-51-1

L-DOPA methyl ester

(S)-3-(3,4-Dihydroxy-phenyl)-2-[3-(4-iodo-phenyl)-propionylamino]-propionic acid methyl ester
132513-20-3

(S)-3-(3,4-Dihydroxy-phenyl)-2-[3-(4-iodo-phenyl)-propionylamino]-propionic acid methyl ester

Conditions
ConditionsYield
With benzotriazol-1-ol; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride In N,N-dimethyl-formamide
L-DOPA methyl ester
7101-51-1

L-DOPA methyl ester

sodium 3-(4-methoxyphenyl)oxiran-2-carboxylate
84382-48-9

sodium 3-(4-methoxyphenyl)oxiran-2-carboxylate

(1S,3S)-6,7-Dihydroxy-1-(4-methoxy-benzyl)-1,2,3,4-tetrahydro-isoquinoline-3-carboxylic acid methyl ester
133761-45-2, 133761-46-3

(1S,3S)-6,7-Dihydroxy-1-(4-methoxy-benzyl)-1,2,3,4-tetrahydro-isoquinoline-3-carboxylic acid methyl ester

(1S,3R)-6,7-Dihydroxy-1-(4-methoxy-benzyl)-1,2,3,4-tetrahydro-isoquinoline-3-carboxylic acid methyl ester
133761-45-2, 133761-46-3

(1S,3R)-6,7-Dihydroxy-1-(4-methoxy-benzyl)-1,2,3,4-tetrahydro-isoquinoline-3-carboxylic acid methyl ester

Conditions
ConditionsYield
With acetic acid In water at 35℃; for 36h;A 145 mg
B 45 mg
L-DOPA methyl ester
7101-51-1

L-DOPA methyl ester

levodopa
59-92-7

levodopa

Conditions
ConditionsYield
With water; sodium chloride In dimethyl sulfoxide at 37℃; Rate constant; also human plasma as reagent;
With sodium carbonate In acetonitrile for 15h;
With potassium hydroxide In methanol
L-DOPA methyl ester
7101-51-1

L-DOPA methyl ester

3-(4-fluoro-3-nitrophenyl)propanoic acid
160877-40-7

3-(4-fluoro-3-nitrophenyl)propanoic acid

(2S)-methyl 3-(3,4-dihydroxyphenyl)-2-[3-(4-fluoro-3-nitrophenyl)propionylamino]propionate
203310-99-0

(2S)-methyl 3-(3,4-dihydroxyphenyl)-2-[3-(4-fluoro-3-nitrophenyl)propionylamino]propionate

Conditions
ConditionsYield
With 1.) TMS-X Yield given. Multistep reaction;
L-DOPA methyl ester
7101-51-1

L-DOPA methyl ester

(R)-N-(tert-butoxycarbonyl)-4-fluoro-3-nitrophenylalanine
173775-54-7

(R)-N-(tert-butoxycarbonyl)-4-fluoro-3-nitrophenylalanine

methyl N-[N-(tert-butyloxycarbonyl)-L-(3,4-dihydroxyphenylalanyl)]-D-4-fluoro-3-nitrophenylalaninate
203311-03-9

methyl N-[N-(tert-butyloxycarbonyl)-L-(3,4-dihydroxyphenylalanyl)]-D-4-fluoro-3-nitrophenylalaninate

Conditions
ConditionsYield
With 1.) TMS-X Yield given. Multistep reaction;
L-DOPA methyl ester
7101-51-1

L-DOPA methyl ester

(S)-N-(tert-butyloxycarbonyl)-4-fluoro-3-nitrophenylalanine

(S)-N-(tert-butyloxycarbonyl)-4-fluoro-3-nitrophenylalanine

methyl N-[N-(tert-butyloxycarbonyl)-L-(3,4-dihydroxyphenylalanyl)]-L-4-fluoro-3-nitrophenylalanine
203311-01-7

methyl N-[N-(tert-butyloxycarbonyl)-L-(3,4-dihydroxyphenylalanyl)]-L-4-fluoro-3-nitrophenylalanine

Conditions
ConditionsYield
With 1.) TMS-X Yield given. Multistep reaction;
L-DOPA methyl ester
7101-51-1

L-DOPA methyl ester

L-dopachrome methyl ester

L-dopachrome methyl ester

Conditions
ConditionsYield
With sodium periodate In phosphate buffer for 0.166667h; pH=6.0; Oxidation; cyclization;
L-DOPA methyl ester
7101-51-1

L-DOPA methyl ester

acetyl chloride
75-36-5

acetyl chloride

2-amino-3-(3,4-diacetoxyphenyl)-propionic acid
39101-99-0

2-amino-3-(3,4-diacetoxyphenyl)-propionic acid

Conditions
ConditionsYield
With trifluoroacetic acid at 20℃;
L-DOPA methyl ester
7101-51-1

L-DOPA methyl ester

(S)-2-Amino-3-(3,4-dioxo-cyclohexa-1,5-dienyl)-propionic acid methyl ester

(S)-2-Amino-3-(3,4-dioxo-cyclohexa-1,5-dienyl)-propionic acid methyl ester

Conditions
ConditionsYield
With 3-methyl-2-benzothiazolinone hydrazone; (S)-(-)-1,1'-binapthyl-2,2-diamine copper(II) In methanol; phosphate buffer at 20℃; pH=8.6; Kinetics; Further Variations:; Catalysts;

7101-51-1Relevant articles and documents

Structural Transformative Antioxidants for Dual-Responsive Anti-Inflammatory Delivery and Photoacoustic Inflammation Imaging

Zhao, Caiyan,Chen, Jingxiao,Ye, Jiamin,Li, Zhi,Su, Lichao,Wang, Junqing,Zhang, Ye,Chen, Jinghua,Yang, Huanghao,Shi, Jinjun,Song, Jibin

supporting information, p. 14458 - 14466 (2021/05/13)

We have synthesized a PEGylated, phenylboronic acid modified L-DOPA pro-antioxidant (pPAD) that can self-assemble into nanoparticles (pPADN) for the loading of a model glucocorticoid dexamethasone (Dex) through 1,3-diol/phenylboronic acid chemistry and hydrophobic interactions for more effective treatment of inflammation. Upon exposure to ROS, pPADN convert into the active form of L-DOPA, and a cascade of oxidative reactions transform it into antioxidative melanin-like materials. Concomitantly, the structural transformation of pPADN triggers the specific release of Dex, along with the acidic pH of inflammatory tissue. In a rat model of osteoarthritis, Dex-loaded pPADN markedly mitigate synovial inflammation, suppress joint destruction and cartilage matrix degradation, with negligible in vivo toxicity. Moreover, in situ structural transformation makes pPADN suitable for noninvasive monitoring of therapeutic effects as a photoacoustic imaging contrast agent.

Small Molecule Inhibits Metal-Dependent and -Independent Multifaceted Toxicity of Alzheimer's Disease

Samanta, Sourav,Rajasekhar, Kolla,Babagond, Vardhaman,Govindaraju, Thimmaiah

, p. 3611 - 3621 (2019/09/10)

Alzheimer's disease (AD) is one of the most devastating forms of dementia, without reliable treatments to cure, delay the onset, or prevent the disease progression. The proposed toxic mechanisms of AD include amyloidogenesis of amyloid β (Aβ), metal ion dyshomeostasis, redox active metal-Aβ inclusion complex formation, and generation of excessive reactive oxygen and nitrogen species (ROS and RNS). The imbalance in redox homeostasis causes oxidative stress, DNA damage, mitochondrial dysfunction, and inflammation, which collectively become a major hurdle in the development of effective therapeutic agents for multifactorial AD. This necessitates a multifunctional strategy to develop effective therapeutic agents to inhibit multifaceted toxicity. In this context, we report a rational design, synthesis, and detailed study to identify a small molecule multifunctional modulator (MFM) inspired by the human origin tripeptide. The lead, MFM 4, chelates and sequesters metal ions, disrupts their redox cycles, prevents excessive ROS production and oxidative stress, ameliorates oxidative DNA damage and mitochondrial dysfunction, and modulates Nrf2 protein signaling under oxidative stress conditions by eliminating the toxic stress elements. The MFM 4 was found to inhibit metal-dependent and -independent Aβ aggregation and qualified as a suitable candidate to inhibit Aβ-induced neuronal toxicity. The NMR spectroscopy study revealed molecular-level interactions of 4 with Aβ42, which explain the mechanism of aggregation inhibition. Furthermore, 4 effectively inhibited inflammation as revealed by reduction in nitric oxide (NO) production in LPS-activated glial cells. These key features make 4 a potential MFM platform to develop therapeutic agents for metal (Cu, Zn and Fe)-dependent and -independent multifaceted Aβ toxicity of AD.

Base/Cryptand/Metal-Free Automated Nucleophilic Radiofluorination of [18F]FDOPA from Iodonium Salts: Importance of Hydrogen Carbonate Counterion

Maisonial-Besset, Aurélie,Serre, Audrey,Ouadi, Ali,Schmitt, Sébastien,Canitrot, Damien,Léal, Fernand,Miot-Noirault, Elisabeth,Brasse, David,Marchand, Patrice,Chezal, Jean-Michel

supporting information, p. 7058 - 7065 (2019/01/04)

As evidenced by the number of publications and patents published in the last years, the radiosynthesis of 6-[18F]fluoro-3,4-dihydroxy-L-phenylalanine ([18F]FDOPA) using the nucleophilic [18F]F- process remains currently a challenge for the radiochemists scientific community even if promising methods for the radiofluorination of electron-rich aromatic structures were recently developed from arylboronate, arylstannane or iodonium salt precursors. In such context, based on the use of an iodonium triflate salt precursor, we optimized a fast and efficient radiofluorination route fully automated and free from any base, cryptand or metal catalyst for the radiosynthesis of [18F]FDOPA. Using this method, this clinically relevant radiotracer was produced in 64 min, 27–38 % RCY d.c. (n = 5), >99 % RCP, >99 % ee., and high Am 170–230 GBq/μmol. In addition, this optimization study clearly highlighted the important role of a triflate-hydrogen carbonate counterion exchange during the radiolabeling process to achieve high fluorine-18 incorporation yields.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 7101-51-1